Investigational drug · Phase 3
Deucrictibant
Also called: PHVS416, PHA121, PHA-022121
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Hereditary Angioedema (HAE), Hereditary Angioedema, Hereditary Angioedema Type I.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
5
3 still active
All registered trials
9
Any phase or sponsor naming "Deucrictibant"
First trial start
2022
Dec 28, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Deucrictibant", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hereditary Angioedema (HAE)
- Hereditary Angioedema
- Hereditary Angioedema Type I
- Hereditary Angioedema Type II
- Hereditary Angioedema Types I and II
- Hereditary Angioedema Attack
- Hereditary Angioedema With C1 Esterase Inhibitor Deficiency
- Hereditary Angioedema - Type 1
- Hereditary Angioedema - Type 2
- Hereditary Angioedema - Type 3
Approved drugs for the same conditions: Hereditary angioedema · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "Deucrictibant" as an intervention, largest first.
- Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAEPivotal-lookingEnrolling by invitation
Pharvaris Netherlands B.V.Industry
NCT06679881 · 170 participants (planned) · Start Feb 1, 2025 · Primary completion Aug 19, 2031
Drug: Deucrictibant · For: Hereditary Angioedema (HAE)
Sites: Birmingham, Alabama; Scottsdale, Arizona; Little Rock, Arkansas · 67 sites in all
- Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary AngioedemaPivotal-lookingEnrolling by invitation
Pharvaris Netherlands B.V.Industry
NCT05396105 · 150 participants (planned) · Start Dec 28, 2022 · Primary completion Jun 2027
Drug: deucrictibant; deucrictibant · For: Hereditary Angioedema; Hereditary Angioedema Type I; Hereditary Angioedema Type II and 14 more
Sites: Birmingham, Alabama; Little Rock, Arkansas; San Diego, California · 60 sites in all
- Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults With Hereditary AngioedemaPivotal-lookingCompleted
Pharvaris Netherlands B.V.Industry
NCT06343779 · 134 participants · Start Feb 26, 2024 · Primary completion Oct 17, 2025
Drug: Deucrictibant, Placebo · For: Hereditary Angioedema; Hereditary Angioedema Type I; Hereditary Angioedema Type II and 11 more
Sites: Birmingham, Alabama; Paradise Valley, Arizona; Little Rock, Arkansas · 76 sites in all
- Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAEPivotal-lookingCompleted
Pharvaris Netherlands B.V.Industry
NCT06669754 · 85 participants · Start Dec 1, 2024 · Primary completion Jul 21, 2026
Drug: Deucrictibant; Placebo · For: Hereditary Angioedema (HAE)
Sites: Little Rock, Arkansas; San Diego, California; Santa Monica, California · 56 sites in all
Pharvaris Netherlands B.V.Industry
NCT04618211 · 74 participants · Start Feb 3, 2021 · Primary completion Sep 23, 2022
Drug: Deucrictibant; Placebo · For: Hereditary Angioedema; Hereditary Angioedema Type I; Hereditary Angioedema Type II and 7 more
Sites: Birmingham, Alabama; Paradise Valley, Arizona; San Diego, California · 36 sites in all
- Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor DeficiencyPivotal-lookingRecruiting
Pharvaris Netherlands B.V.Industry
NCT07266805 · 48 participants (planned) · Start Oct 16, 2025 · Primary completion Jun 2027
Drug: Deucrictibant; Placebo and 3 more · For: Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)
Sites: San Diego, California; Walnut Creek, California; St Louis, Missouri · 32 sites in all
Pharvaris Netherlands B.V.Industry
NCT05047185 · 34 participants · Start Apr 19, 2022 · Primary completion Jun 30, 2025
Drug: Deucrictibant low dose; Deucrictibant high dose and 1 more · For: Hereditary Angioedema; Hereditary Angioedema Type I; Hereditary Angioedema Type II and 7 more
Sites: Birmingham, Alabama; Paradise Valley, Arizona; St Louis, Missouri · 19 sites in all
Institute for Asthma and AllergyResearch network
NCT07046806 · 10 participants (planned) · Start Mar 10, 2025 · Primary completion Apr 1, 2026
Drug: Deucrictibant XR tablet; Placebo comparator to XR tablet and 2 more · For: Hereditary Angioedema (HAE); Angioedema; Bradykinin-mediated Angioedema and 1 more
Sites: Wheaton, Maryland
Pharvaris Netherlands B.V.Industry
NCT07759141
Drug: Deucrictibant IR · For: Hereditary Angioedema
Newest research
PubMed records naming it or its code names, newest first.
- Landscape of hereditary angioedema in China: A multicenter cross-sectional questionnaire survey.
Xu Y, Chen W, Craig T, et al. · World Allergy Organ J 2026
- Deucrictibant: a novel oral on-demand treatment for hereditary angioedema.
Zuraw BL, Christiansen SC · Lancet 2026
- Oral deucrictibant for on-demand treatment of hereditary angioedema attacks: a phase 3, multicentre, randomised, double-blind, placebo-controlled crossover trial.
Riedl MA, Li PH, Adatia A, et al. · Lancet 2026
- Evaluating deucrictibant for the treatment of hereditary angioedema.
Bui V, Stone S, Bhattarai B, et al. · Expert Opin Pharmacother 2026
- [Current and future therapies for bradykinin-mediated angioedema].
Fasshauer M, Dominas N · Dermatologie (Heidelb) 2026
- Oral deucrictibant for on-demand treatment of hereditary angioedema attacks (RAPIDe-1): a randomised, double-blind, placebo-controlled, phase 2 trial.
Maurer M, Stobiecki M, Valerieva A, et al. · Lancet Haematol 2026
Also in development for Hereditary Angioedema (HAE)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.